Story
US Prescription Volume Rose 1.9% in July, Driven by Specialty and GLP-1 Drugs, Evercore Says

Total prescription volumes in the United States rose 1.9% year-over-year in July, reaching 575 million prescriptions, according to a new analysis released by Evercore. The data also showed a 1.6% increase compared to the previous month, indicating sustained demand across the pharmaceutical sector.
Specialty and Branded Drugs Lead Growth
The July increase was primarily driven by strong performance in higher-value categories. According to Evercore's report, key growth segments included:
- Specialty prescriptions: Jumped 8.5% year-over-year.
- Branded prescriptions: Increased 3.7% from the same period last year.
- Generic prescriptions: Climbed a more modest 1.6%.
Mail order services continued to gain traction, with volumes increasing 8.4% year-over-year to capture approximately 13.0% of the total market share. However, the report noted a deceleration in the broader medical specialty market, with sales growth slowing to approximately 12% year-over-year in June, down from a peak of 24% in July 2025.
GLP-1 Demand Surges Amid New Medicare Program
AdPrescriptions for GLP-1 drugs, a class that includes popular weight-loss and diabetes treatments, reached approximately 12.0 million in July. This represents a 29% year-over-year increase and a 4% rise from June, with the category now accounting for about 2.1% of all prescriptions.
The launch of the Medicare GLP-1 Bridge program on July 1, 2026, appears to have boosted demand. The program sets a $50 monthly copay for beneficiaries on drugs like Wegovy, Zepbound, and Foundayo. Combined weekly new prescriptions for these three drugs averaged 780,000 in the last three weeks of July, an 11.6% increase from the 698,000 average in June. The share of cash-pay patients for GLP-1s also rose to approximately 18%, up from roughly 5% a year prior.
Inflation and Market Context
In other market indicators, generic drug deflation eased slightly to 7.1% in June, compared to 7.8% in May, Evercore reported. Inflation for branded drugs remained flat during the same period. The slowing growth in oncology sales, which grew approximately 11% year-over-year versus a 25% peak, suggests a moderating trend in some high-growth specialty areas.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.